Scholarlink

Background <p>Parkinson’s disease (PD) multimodal complex treatment (PD-MCT) is an inpatient therapeutic programme specifically designed for patients exhibiting parkinsonian symptoms. Established in Germany, this comprehensive approach addresses the multifaceted challenges associated with the management of PD, particularly in advanced stages or when complications such as motor fluctuations, dyskinesia, or non-motor symptoms become pronounced. The programme integrates pharmacological optimization, physiotherapy, occupational therapy, speech therapy, and psychological support, among other complementary therapies, to enhance patient outcomes holistically. Despite its availability for seventeen years, only seven studies evaluating the effectiveness of PD-MCT have been conducted. In this study we evaluated the effects of PD-MCT with a special focus on gait, hypothesizing an improvement after the treatment.</p> Methods <p>In this single-centre cohort study at a German university hospital we included patients with PD diagnosed by the Movement Disorder Society (MDS) criteria, aged 18–85 years, legal capacity to consent and admitted for treatment with PD-MCT. We assessed changes in motor and non-motor symptoms using Wilcoxon’s signed rank test on pre/post measurements of part III of the motor part of the MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the Parkinson’s Disease Questionnaire (PDQ-39) and the Timed Up and Go Test (TUG). As a particular emphasis was placed on gait analysis we objectively measured gait throughout the treatment period using advanced mobile sensor technology and analysed gait speed, stride length and lift height using linear mixed effects models.</p> Results <p>In our sample of 43 PD patients we found significant improvements in MDS-UPRDRS part III (V = 679, <i>p</i> = 0.001), PDQ-39 (V = 770, <i>p</i> &lt; 0.001) and TUG (V = 753.5, <i>p</i> &lt; 0.001) values. as well as in the assessed gait parameters gait speed (t = 66.44, <i>p</i> &lt; 0.001), stride length (t = 62.67, <i>p</i> &lt; 0.001) and lift height (t = 28.16, <i>p</i> &lt; 0.001).</p> Conclusions <p>Our results underscore the added value of a multimodal inpatient approach, thereby supporting its role as a justified investment in the management of complex PD cases. This work contributes to the expanding body of evidence advocating for integrated, multidisciplinary care models in the treatment of neurodegenerative disorders.</p> Trial registration <p>This study has not been registered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multidisciplinary inpatient care for Parkinson’s disease: a single-centre cohort study on improvements in gait, overall motor function, and quality of life

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月2日

查看全文
  • Urs Kleinholdermann,
  • Felicitas C. J. Mügge,
  • Tiziano Carapezza,
  • Lukas Decher,
  • Lars Timmermann,
  • David J. Pedrosa

摘要

Background

Parkinson’s disease (PD) multimodal complex treatment (PD-MCT) is an inpatient therapeutic programme specifically designed for patients exhibiting parkinsonian symptoms. Established in Germany, this comprehensive approach addresses the multifaceted challenges associated with the management of PD, particularly in advanced stages or when complications such as motor fluctuations, dyskinesia, or non-motor symptoms become pronounced. The programme integrates pharmacological optimization, physiotherapy, occupational therapy, speech therapy, and psychological support, among other complementary therapies, to enhance patient outcomes holistically. Despite its availability for seventeen years, only seven studies evaluating the effectiveness of PD-MCT have been conducted. In this study we evaluated the effects of PD-MCT with a special focus on gait, hypothesizing an improvement after the treatment.

Methods

In this single-centre cohort study at a German university hospital we included patients with PD diagnosed by the Movement Disorder Society (MDS) criteria, aged 18–85 years, legal capacity to consent and admitted for treatment with PD-MCT. We assessed changes in motor and non-motor symptoms using Wilcoxon’s signed rank test on pre/post measurements of part III of the motor part of the MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the Parkinson’s Disease Questionnaire (PDQ-39) and the Timed Up and Go Test (TUG). As a particular emphasis was placed on gait analysis we objectively measured gait throughout the treatment period using advanced mobile sensor technology and analysed gait speed, stride length and lift height using linear mixed effects models.

Results

In our sample of 43 PD patients we found significant improvements in MDS-UPRDRS part III (V = 679, p = 0.001), PDQ-39 (V = 770, p < 0.001) and TUG (V = 753.5, p < 0.001) values. as well as in the assessed gait parameters gait speed (t = 66.44, p < 0.001), stride length (t = 62.67, p < 0.001) and lift height (t = 28.16, p < 0.001).

Conclusions

Our results underscore the added value of a multimodal inpatient approach, thereby supporting its role as a justified investment in the management of complex PD cases. This work contributes to the expanding body of evidence advocating for integrated, multidisciplinary care models in the treatment of neurodegenerative disorders.

Trial registration

This study has not been registered.